Quest Diagnostics 1998 Annual Report Download - page 12

15
Investor Information
Common Stock
Shares in Quest Diagnostics
Incorporated (ticker symbol:
“DGX”) are listed on the New York
Stock Exchange. Options on Quest
Diagnostics shares are traded on the
Chicago Board Options Exchange.
Corporate Headquarters
One Malcolm Avenue
Teterboro, New Jersey 07608
Telephone: [phone]
Annual Meeting
The next annual meeting of share-
holders is scheduled to be held in
late June, 1999 in New York City. A
proxy statement is expected to be
mailed to shareholders during May,
1999.
Additional Information
All inquiries should be addressed
to: Investor Relations Department
Quest Diagnostics Incorporated
One Malcolm Avenue
Teterboro, New Jersey 07608
Telephone: [phone]
Annual Report on Form 10-K
A copy of the Quest Diagnostics
1998 Annual Report on Form 10-K,
filed with the Securities and
Exchange Commission, is contained
in this Annual Report, starting after
page 14. Additional copies are
available without charge by contacting
the Investor Relations Department.
Internet Access
Corporate news releases, our annual
report, Forms 10-K and 10-Q and
other information about the
company are available through
Quest Diagnostics’ web site on the
Internet:
http://www.questdiagnostics.com
Transfer Agent and Registrar
Harris Trust and Savings Bank
311 West Monroe Street
Chicago, Illinois 60606
Telephone: [phone]
For the hearing impaired, Harris
Bank has a Telecommunications
Device for the Deaf (TDD)
telephone. The listing is Harris
Bank Hearing Impaired Telephone:
TDD 312-461-5633.
Report change of address to
Harris Bank at the above address.
Quest Diagnostics does not pay any
dividends on common stock.
‘Safe Harbor’ Statement under the Private
Securities Litigation Reform Act of 1995
The statements in this Annual
Report which are not historical facts
or information are forward-looking
statements. These forward-looking
statements involve risks and uncer-
tainties that could cause the out-
come to be materially different.
Certain of these risks and uncertain-
ties are listed in the 1998 Form 10-K
Annual Report. These risks and
uncertainties include heightened
competition, impact of changes
in payor mix, adverse actions by
governmental and other third-party
payors, the impact upon Quest
Diagnostics’ collection rates or
general or administrative expenses
resulting from compliance with
Medicare administrative policies,
adverse results from pending
governmental investigations,
reduction in tests ordered by exist-
ing customers, material increases in
premiums for insurance coverage,
denial of licensure, computer or
other system failures, development
of technologies that substantially
alter the practice of medicine and
changes in interest rates.
Compliance
Quest Diagnostics is committed to
the highest ethical standards and
complying with all applicable laws
and regulations that govern its
business operations, including those
that apply to reimbursement for
testing under the federal Medicare
and Medicaid programs.
Quest Diagnostics requires that all
employees abide by these laws, rules
and regulations and provides annu-
al compliance training for all
employees. Quest Diagnostics is
committed to protecting the health
and safety of its employees as well as
the environmental resources of the
communities in which it operates.
The Raymond Gambino
Quality Award
The purpose of the Raymond
Gambino Quality Award is to
encourage and recognize quality
excellence within Quest
Diagnostics. The award is named
for Quest Diagnostics’ distinguished
Chief Medical Officer Emeritus
whose long career includes service
as Director of Laboratories and
Chief Pathologist at St. Luke’s-
Roosevelt Hospital in New York City
as well as a tenured professorship of
pathology at the Columbia
University College of Physicians and
Surgeons.
1998 Recipients:
Denver, Colorado
Horsham, Pennsylvania
San Diego, California
1998 Challenger:
Cambridge, Massachusetts
Trademarks
QUEST, QUESTNET, QUEST DIAGNOSTICS
and the associated Logo are trade/servicemarks
of Quest Diagnostics Incorporated. QUICK-
STREP and CHEM-SCREEN are registered ser-
vicemarks of CLMP, INC. SMARTECH is a trade-
mark of CLMP, Inc. NICHOLS INSTITUTE is a
servicemark and NICHOLS ADVANTAGE is a
trademark of Quest Diagnostics Incorporated.
QUICK-INTRAOPERATIVE and QUICK-PAK are
trademarks of Nichols Institute Diagnostics, Inc.
QUEST INFORMATICS is a servicemark of
Quest Diagnostics Incorporated.
HercepTest is a trademark of Dako Corporation.
Herceptin is a trademark of Genentech, Inc.
Neither this report nor any statement
contained herein is furnished in connection with
any offering of securities or for the purpose of
promoting or influencing the sale of securities.
Produced by Quest Diagnostics’ Corporate Communications Department; Design: Q. Cassetti; Photography: Ed Wheeler, Fred Smith and Associates; Printing: Daniels Printing